Vivos Therapeutics Inc's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 133 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.45.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vivos Therapeutics Inc's Score
Industry at a Glance
Industry Ranking
133 / 204
Overall Ranking
324 / 4565
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Vivos Therapeutics Inc Highlights
StrengthsRisks
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.39% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 17.44M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 17.44M.
Overvalued
The company’s latest PE is -0.21, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.10M shares, decreasing 6.15% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.05.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.